Key result
LINC01559 is upregulated in pancreatic cancer and accelerates cell proliferation and migration by acting as a ceRNA for YAP via sponging miR-607 and interacting with YAP protein.
Why the study?
Pancreatic cancer is one of the most fatal cancers, and increasing evidence suggests the involvement of long noncoding RNAs in cancer initiation and progression.
LINC01559 accelerates pancreatic cancer progression through a YAP-mediated pathway, suggesting a potential therapeutic target.
Preclinical data leave open LINC01559 as a pancreatic cancer target; human validation required before any clinical consideration.
Pancreatic cancer (PC) is one of the top two most fatal cancers, with the poorest survival rate among all human malignancies. Increasing evidence suggests the involvement of long noncoding RNAs (lncRNAs) in the initiation and progression of various cancers. Herein, we investigated the role of lncRNA LINC01559 in PC. Several online databases indicated that LINC01559 was at a low expression in normal pancreatic tissues but was obviously upregulated in PAAD tissues. Further, our results showed that LINC01559 was stimulated in PC cell lines relative to normal controls. Furthermore, we validated that LINC01559 facilitated PC cell proliferation and migration in vitro. Also, silencing LINC01559 obstructed PC cell growth in vivo. Besides, LINC01559 was revealed to be mainly in the cytoplasm of PC cells and therefore served as a ceRNA of Yes-associated protein (YAP) in PC cells via sponging miR-607. Surprisingly, we also proved that LINC01559 could interact with YAP protein, which might hinder YAP phosphorylation and enhance YAP transcriptional activity in PC cells. Furthermore, we demonstrated that YAP was the downstream effector in LINC01559-regulated PC development. Collectively, our findings unmasked that LINC01559 accelerates PC progression through relying on YAP, providing a new potential target for clinical treatment of patients with PC.
No takes yet. Share an insight, caveat, or question.
Lou et al. (2019) studied Pancreatic cancer. LINC01559 vs. Normal controls was evaluated on Pancreatic cancer cell proliferation, migration, and growth. LINC01559 is upregulated in pancreatic cancer and accelerates cell proliferation and migration by acting as a ceRNA for YAP via sponging miR-607 and interacting with YAP protein.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: